Category Archives: Multaq
Middle-aged Dronedarone Users Have Higher Risk of Hospitalization

New study results reveal that patients age 61 and younger treated with the heart rhythm drug dronedarone (Multaq) have a higher risk for hospitalization than those with treated other anti-arrhythmic drugs. The study, published in Circulation: Cardiovascular Quality and Outcomes, … Continue reading
Multaq Patients Had Double Death Risk in Halted Trial
A study has found that patients taking < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq to control serious, permanent atrial fibrillation, may face a doubled risk of death. Such Multaq patients also face a much higher risk of suffering a heart attack and stroke, according to … Continue reading
Multaq Side Effect Concerns Prompt Restrictions in Europe
Use of < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq, the Sanofi-Aventis heart drug that has been linked to heart, liver and lung problems, has been restricted by regulators in Europe. According to a report from The Wall Street Journal, a committee of the European Medicines … Continue reading
Multaq Faces FDA Scrutiny As Safety Concerns Mount
The U.S. Food & Drug Administration (FDA) said yesterday that it is continuing to review the safety of < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq, as more and more specialists report they are no longer prescribing the drug. Multaq has been linked to a number … Continue reading
Multaq Maker Issues Formal Alert for Halted Study
Sanofi-Aventis has formally alerted doctors that a clinical trial involving < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone) was halted because patients in the study’s Multaq group were dying at more than twice the rate of that of patients taking placebo. “Healthcare professionals are advised … Continue reading
Canada Reviewing Multaq Over Heart Worries
Add Canada to the list of countries taking a deeper look into prescription medication, < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone). Health Canada, said CTV News, is reviewing the drug’s safety. Multaq is already approved to treat temporary Atrial Fibrillation (AF), or abnormal heart … Continue reading
New Multaq Alert Issued by FDA
Following an expanded European Medicines Agency (EMA) probe, the U.S. Food and Drug Administration (FDA), as expected, announced that it will be reviewing information from a < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq clinical trial that was stopped over higher-than-expected adverse heart reactions in trial … Continue reading
Multaq Heart Side Effects Under Review in Europe
Sanofi is facing an expansion of an ongoing review of its atrial fibrillation (AF) treatment, < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone). The European Medicines Agency (EMA) found that a study revealed possible heart risks in patients using the drug, said FiercePharma. The Agency … Continue reading
Multaq Trial Halted Due to Significant Increase in Heart Problems
A clinical trial for < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone) has ended early after a significant number of heart-related side effects were seen in the study. The trial, known as the PALLAS study, was testing Multaq’s as a treatment for permanent atrial fibrillation. … Continue reading
Multaq Patients Should Undergo Liver Function Tests
European regulators recently warned that < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (donedarone) could put patients at risk for severe liver injuries. The European Medicines Agency (EMA) is now recommending that doctors perform liver function tests before treating atrial fibrillation patients with Multaq. The European … Continue reading